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From Vessel Sprouting to Normalization
Role of the Prolyl Hydroxylase Domain Protein/Hypoxia-Inducible Factor
Oxygen-Sensing Machinery
Cathy Coulon, Maria Georgiadou, Carmen Roncal, Katrien De Bock,
Tobias Langenberg, Peter Carmeliet
Abstract—The accepted model of vessel branching distinguishes several endothelial cell fates. At the forefront of a vessel
sprout, “tip cells” guide the sprouting vessel toward an angiogenic stimulus. Behind the tip, “stalk cells” proliferate to
elongate the vessel branch and create a lumen. In mature vessels, endothelial cells acquire a streamlined shape to
optimally conduct blood flow. For this purpose, endothelial cells switch to the “phalanx” cell fate, which is characterized
by quiescent and nonproliferating cells aligned in a tight cobblestonelike layer. Vessel maturation also requires the
recruitment of mural cells (ie, smooth muscle cells and pericytes). These cell fates are often altered in pathological
conditions, most prominently during the formation of tumor vasculature. Given the essential role of hypoxia as the
driving force for initiating angiogenesis, it is not surprising that the hypoxia-sensing machinery controls key steps in
physiological and pathological angiogenesis. (Arterioscler Thromb Vasc Biol. 2011;31:00-00.)
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Angiogenesis is a dynamic process that is tightly regu-lated by oxygen-sensing mechanisms. The prolyl hy-
droxylase domain proteins (PHDs) are oxygen-sensing en-
zymes that belong to the evolutionarily conserved
superfamily of iron-containing 2-oxoglutarate–dependent di-
oxygenases. This family consists of 3 PHDs (PHD1–3) and
the factor inhibiting hypoxia-inducible factor (HIF) (FIH).1
Under well-oxygenated conditions, PHDs hydroxylate con-
served prolyl residues of the HIF- subunits, thereby gener-
ating a binding site for the von Hippel–Landau tumor
suppressor protein, which targets HIF- for proteosomal
degradation. When oxygen levels decrease, the hydroxylation
activity of the PHDs is reduced, leading to HIF- accumula-
tion. On binding to HIF-, the HIF-/ complex translocates
and activates transcription of numerous genes, including
those regulating survival, metabolism, and angiogenesis.2 In
normoxia, the transcriptional activity of HIF is reduced by
hydroxylation of a conserved asparagine residue by FIH.3
Emerging evidence suggests that HIF-1 and HIF-2 have
distinct nonoverlapping roles in angiogenesis.4 PHD2 is a key
family member and, consistent with this report, its deficiency
disrupts development.5,6 Oxygen-independent pathways for
the regulation of HIFs and PHDs also exist.1,7 Moreover, the
oxygen sensors can hydroxylate other proteins, some of
which are associated with angiogenesis.1 Important knockout
phenotypes of these PHD/HIF molecules in mice are listed in
the Table.
Oxygen Sensing in the Endothelial Sprout
Vessel branching is regulated by growth factors8,9 and guid-
ance cues.10,11 Gradients of some of these signals are sensed
by the tip cell, which translates them into directional migra-
tion. Tip cells are polarized, have numerous filopodia that
probe the environment while the cell migrates toward an
angiogenic stimulus, and do not form a lumen.8 They have a
specific molecular signature, characterized by the expression
of vascular endothelial growth factor (VEGF) receptor 2
(VEGFR2), VEGFR3, platelet-derived growth factor-,
Unc5B, neuropilin, deltalike ligand-4 (Dll4), CXCR4, and
Ephrin-B2,12–15 among other markers.16 Dll4 binds to the
Notch1 receptor of neighboring cells, thereby inducing a stalk
cell phenotype.17 Stalk cells trail behind the tip, proliferate,
elongate the stalk, form a lumen, and connect to the circula-
tion. They do not extend filopodia but rather form tight
junctions and prevent endothelial cell (EC) retraction.16
Although hypoxia is a strong stimulus for angiogenesis, it
remains unclear how hypoxia-induced signaling regulates the
various steps of vessel branching. Hypoxia and HIF-1
enhance the expression of VEGFR2,8 which induces Dll4
expression in the tip cell. Components of the oxygen-sensing
machinery also modulate the Notch signaling pathway. For
instance, HIF-1 interacts with the Notch intracellular do-
main and increases its activity.18 Moreover, HIFs stimulate
transcription of the Notch targets Hey1, Hey2, and Dll4,19,20
whereas HIF-1 heterozygosity decreases the levels of acti-
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vated Notch1 and its target genes Dtx1 and Nrarp.21 FIH-1
hydroxylates ankyrin repeat domains in Notch receptors,
thereby decreasing their activity and the ability of FIH to
hydroxylate HIFs.22,23
Several genetic studies suggest a role for HIF-1 in vessel
sprouting. Loss of HIF-1 in ECs attenuates the expression of
hypoxia-inducible angiogenic genes and reduces EC prolif-
eration under hypoxic conditions.24,25 EC-specific HIF-1–
deficient mice do not exhibit an overt phenotype in baseline
conditions but show reduced tumor growth and vasculariza-
tion because of attenuated endothelial expression of VEGF
and VEGFR2. HIF-2 levels are not upregulated by the
absence of HIF-1, suggesting that HIF-2 differentially
regulates EC physiological features in vivo.25 This is in line
with previous reports26,27 that embryos lacking HIF-1 dis-
play vascular defects that are not rescued by HIF-2. Con-
versely, HIF-1 stimulates neovascularization and improves
functional recovery of ischemic tissues in adults.28 Thus,
although HIF-1 controls vessel sprouting, HIF-2 seems to
mediate the maintenance of the newly formed sprout.
Oxygen Sensing and Endothelial Quiescence
Once a functional branch is established and is ready to fuse,
the explorative behavior of the tip cell and the proliferative
Table. Summary of Phenotypes in Knockout Mice of PHD/HIF Oxygen-Sensing Molecules
Gene Genotype Phenotype
PHD1 / Hypoxia tolerance of skeletal muscle and liver due to reprogramming to anaerobic metabolism72,73
and decreased cyclin D1 levels and mammary gland proliferation74
PHD2 / Normal vascular development; tumor vessel normalization, leading to reduced metastasis and
tumor invasiveness due to improved tumor oxygenation30
/ (Prenatal) Embryonic lethality due to placental and heart defects5
/ (Postnatal) Increased angiogenesis75 and polycythemia and congestive heart failure76
Silencing in tumor cells Increased tumor growth and angiogenesis42
Endothelial haplodeficiency Tumor vessel normalization (phenocopy of the PHD2/ phenotype)30
PHD3 / Hypofunctional sympathoadrenal system and reduced blood pressure77
PHD1; PHD3 /;/ Viable and fertile with smaller litters and moderate erythrocytosis43
PHD3; PHD2 /;/ (Postnatal) Premature lethality due to hepatic steatosis and dilated cardiomyopathy78
FIH / Viable, but reduced, body mass; enhanced metabolic rate; and insulin sensitivity79
HIF-1 / Protection against vascular remodeling during pulmonary hypertension and impaired physiological
response to chronic hypoxia80
Endothelial inactivation Impaired tumor angiogenesis25
HIF-1KI/:HIF-2
knocked in HIF-1 allele
Viable and decreased incidence of thymic lymphomas in a p53 mutant mouse model21
HIF1KI/KI:HIF-2 knocked
into both HIF-1 alleles
Embryonic lethality and embryonic stem cells generate more proliferative and vascularized
teratomas21
/ Embryonic lethality due to (cardio)vascular defects and impaired tumor angiogenesis26,27,81–83
HIF-2 / Viable and fertile, protection against hypoxia-induced pulmonary vasculature remodeling,84 and
reduced retinal neovascularization after oxygen-induced retinopathy85
Endothelial inactivation Defects in vessel integrity and tumor neovascularization41
/ (Postnatal) Anemia86
/ (Prenatal) Background-dependent phenotype: embryonic lethality due to vascular defects and vascular
disorganization in yolk sac and embryo (CD1 and ICR/129Sv outbred)35,87; minimal viability due to
multiple organ pathological features, metabolic abnormalities, and hematopoietic defects;
defective catecholamine metabolism and bradycardia (C57/Black6 and 129 interbred)37–39; defects
in lung maturation; and acute respiratory distress (129/Sv x Swiss)36
HIF-1;;
HIF-2
/;/ Embryonic lethality due to defective placental vascularization88
HIFdn Endothelial dominant
negative
Embryonic lethality due to cardiovascular defects and an immature and disorganized vascular
network89
HIF-3 (IPAS
splice variant)
Oligo antisense in the
cornea
Induced angiogenesis90
HIF-3 (NEPAS
splice variant)
/ Enlargement of the right ventricle and impairment of lung remodeling91
HIF-1 Endothelial-specific
inactivation
Partial embryonic lethality due to hepatic vascular defects and impaired energy homeostasis; and
liver lesions, impaired lipid serum homeostasis, and hyperactive metabolism in adulthood92
/ Embryonic lethality, insufficient angiogenesis and bronchial arch development, defective placental
vascularization and vascular development, and altered placental cell fate determination93–96
ICR indicates ●●●; IPAS, ●●●; NEPAS, ●●●.
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nature of the stalk cell need to be suppressed. Recent studies
report the involvement of HIF/PHD oxygen sensors in vessel
stabilization. Angiopoietin-1 induces normalization of imma-
ture vessels, a process associated with reduced PHD2 expres-
sion.29 Via upregulation of HIF-2, haplodeficiency of PHD2
also induces tumor vessel normalization.30 PHD2 haplodefi-
ciency in tumor ECs does not affect vessel density, area, or
lumen size; however, it “normalizes” the endothelial lining,
barrier, and stability. This does not affect primary tumor
growth. It does improve tumor oxygenation and establish a
tight impenetrable endothelial barrier, which prevents a
metastatic switch and impedes intravasation of tumor cells
and metastasis, overall resulting in prolonged survival of
tumor-bearing mice. Gene profiling revealed a lower induc-
tion of HIF-1–dependent metastatic genes and an upregu-
lation of the junctional protein VE-cadherin and the VEGF-
trap soluble VEGFR1.30 VE-cadherin has induced a normalized
endothelial phenotype indirectly by inhibiting VEGF-driven
proliferation and survival.31,32 It also inhibits proliferation of
ECs in cooperation with soluble VEGFR1 to induce EC
quiescence.33 Consistently, its expression is specifically up-
regulated by HIF-2 but not by HIF-1.34
Genetic HIF-2–deficient studies show variable pheno-
types depending on the genetic background. In a CD1 strain,
loss of HIF-2 causes improper remodeling of nascent
vessels into larger conduits,35 whereas in other backgrounds,
loss of HIF-2 causes abnormal organ development or
homeostasis without apparent vascular deficits.36–39 Silencing
HIF-2 by approximately 50% in host mice leads to the
formation of an aberrant vascular network in tumors through
reduced expression of Ephrin-A1 in ECs. This is not because
of reduced sprouting vessels or hypoxic EC proliferation;
rather, it is because of impaired remodeling of the microvas-
culature.40 Consistently, HIF-2 deficiency in ECs results in
increased vessel permeability and defective tumor neovascu-
larization by decreasing the expression of genes involved in
adhesion and extracellular matrix formation and angiogene-
sis.41 Notably, loss of HIF-2 in ECs reduces metastasis
(possibly because primary tumor growth was also reduced),41
whereas HIF-2 upregulation in PHD2-haplodeficient mice
also reduces metastasis (via the previously mentioned mech-
anism of tumor vessel normalization).30 In contrast, PHD2
inactivation in tumor cells accelerates tumor growth via
HIF-independent NF-B pathway signaling.42 Also, complete
inactivation of PHD2 in mice after birth stimulates the out-
growth of supernumerary vessels in healthy organs,43 indicating
that the effects of PHD2 in the vasculature are dose dependent.
Bone Marrow–Derived Progenitors, Oxygen
Sensing, and Angiogenesis
Recruitment of a heterogeneous population of bone marrow–
derived cells (BMDCs), containing progenitors of the endo-
thelial, pericyte, and hematopoietic lineage, may also contrib-
ute to vessel formation and maturation.44 Some of the signals
that regulate the mobilization and homing of BMDCs to
hypoxic areas have been characterized. VEGFR1 and its
ligands (ie, VEGF and PlGF) induce BMDC mobilization and
recruitment to ischemic regions45–47 in response to HIF-1
stabilization.48,49 By binding CXCR4-positive BMDCs, stro-
mal cell–derived factor-1 (SDF-1/CXCL12) promotes re-
cruitment and retention of endothelial progenitor cells in
ischemic tissues. HIF-1 upregulates CXCR4 receptor ex-
pression and enhances SDF-1 expression in ECs, thereby
promoting adhesion, migration, and retention of CXCR4
BMDCs.13,50 The inhibition of SDF-1 in ischemic tissue or of
CXCR4 in circulating cells prevents endothelial progenitor
cell recruitment to sites of injury.51 HIF-1–dependent in-
duction of SDF-1 was documented in various angiogenesis
models.52,53 Interestingly, hypoxic BM regions also exhibit
increased SDF-1 expression and endothelial progenitor cell
retention, suggesting that tissue hypoxia may constitute a
more general mechanism governing stem cell retention.51
HIF-1–dependent induction of SDF-1 is also capable of
recruiting bone marrow–derived CD45 cells of the mono-
cytic lineage.54 Monocyte-derived cells secrete matrix metal-
loproteases, which contribute to angiogenesis by degrading
basement membranes and extracellular matrix components,
thereby enhancing the release of proangiogenic factors from the
extracellular matrix.55–58 In addition, macrophages release
the peptide PR39, which inhibits HIF-1 degradation, am-
plifying the hypoxic response.59 Hypoxic induction of matrix
metalloproteases contributed to cancer cell metastasis by
degrading extracellular matrix components.60–66 Develop-
ment of hypoxia during antiangiogenic treatment may trigger
recruitment of BDMCs, which can contribute to revascular-
ization after treatment cessation. Interestingly, recent evi-
dence links reduced tumor vascularization and growth during
chemotherapy with a reduction in BMDC mobilization. Anthra-
cyclines inhibit HIF-1 activity by disrupting its binding to
DNA, thereby decreasing levels of HIF-1 target genes (eg,
VEGF, SDF-1, and stem cell factor).67
Mural Cells, Oxygen Sensing, and
Vessel Maturation
Mural cells (ie, pericytes in capillaries and vascular smooth
muscle cells in larger blood vessels) provide vessel stabiliza-
tion and regulate vessel perfusion.68 In PHD2-haplodeficient
mice, the reduction of PHD2 levels in ECs promotes pericyte
coverage of tumor ECs via HIF-2–dependent mechanisms,
thereby rendering the vessels more mature, tight, and stable.30
In another experimental setting, inhibition of HIF-1 reduces
mural cell association with tumor ECs.69 Furthermore, noise-
induced mechanical and metabolic stress causes local hypox-
ia in the cochlear microvasculature, which promotes the
stabilization of HIF-1. The subsequent upregulation of
VEGF in both pericytes and ECs results in exaggerated
pericyte coverage and abnormal vessel morphological fea-
tures, yielding leaky and dysfunctional vessels.70 Another
link between oxygen sensing and vessel maturation may be
platelet-derived growth factor receptor- signaling, which
controls mural cell recruitment and can be suppressed by
VEGF-induced activation of VEGFR2.71
Conclusions
An important trigger activating the formation of a new blood
vessel is the lack of oxygen in surrounding tissues. Therefore,
it is not surprising that ECs and other cells composing the
mature vessel are able to sense oxygen. Although previous
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research has mainly focused on the role of VEGF, evidence is
emerging that oxygen levels inside the vessel wall itself
determine the fate of the developing sprout. Therefore,
exploring the role of HIF-, a master modulator of the
hypoxic response, and its regulators (ie, PHD oxygen sen-
sors) is crucial to improving our understanding of angiogen-
esis. Inside the endothelium, HIF-1 is presumed to control
sprouting, whereas HIF-2, in a dose-dependent way, ensures
vessel quiescence and stability. In mural cells, a similar dose
dependency also seems to determine the HIF-1–mediated
response to hypoxia; however, it is still unclear whether
HIF-2 is also involved in conferring adequate pericyte or
smooth muscle cell function. In addition, HIF-1 has trig-
gered the recruitment of progenitor cells that could also
contribute to vessel stabilization.
The knowledge that the oxygen machinery influences all
players conferring a mature functional vessel has broad
clinical implications. Increasing tumor hypoxia through anti-
angiogenic therapy induces the PHD/HIF oxygen-sensing
machinery that is likely to reestablish the vasculature as soon
as therapy ceases. Targeting the HIF transcriptional system in
selective cell types may provide an elegant way to overcome
this survival mechanism. Furthermore, treatment of diseases
characterized by insufficient angiogenesis could also benefit
from a cell-specific modulation of the HIF/PHD system.
Therefore, more research is required to characterize the
molecular pathways initiated by the oxygen sensors.
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